This site is intended for healthcare professionals

OlympiA phase III trial of Lynparza for the treatment of BRCA-mutated high-risk HER2-negative early breast cancer will reported early.- AstraZeneca + Merck Inc.

Read time: 1 mins
Last updated:18th Feb 2021
Published:18th Feb 2021
Condition: Breast Cancer HER2- BRCA mutated
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest